BÜHLMANN has been the market leading provider of faecal calprotectin assays in the UK for over 10 years, holding a significant portion of the market share, as recorded on the National External Quality Assurance Scheme (NEQAS). The BÜHLMANN results are split across the two main laboratory assays: fCAL ELISA and fCAL turbo assays. There is
The #1 Resource for Calprotectin in the UK and Eire
- [email protected]
- +44 (0) 23 8048 3000
Category: Uncategorized
Calprotectin Testing Goes Mobile With advances in technology and the ubiquitous use of mobile devices, a huge opportunity has arisen to change the way some healthcare services are provided. This is especially applicable to the management of chronic conditions. With most people owning a mobile device or tablet this becomes a convenient way for patients to
BÜHLMANN application specialist Christina Gabris has recently visited the UK to validate some new instrument protocols for the fCAL turbo assay. Christina spent time in hospitals around Newcastle to optimise CE marked protocols for the Beckman AU5800 and AU680. The range of instruments with CE marked protocols for fCAL turbo has now been expanded to 28 including: Roche: cobas c501 & c502, cobas c701
Labs are receiving increasing faecal calprotectin tests requests since NICE published Diagnostic Guideline 11: ‘Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel’. This recommends faecal calprotectin as a first-line test for patients presenting with gastrointestinal (GI) symptoms indicative of IBS or IBD. Pam Bowe, team manager in the Department of Biochemistry at the Cumberland Infirmary, describes the evolution of her laboratory procedures to cope
Read about the work at Luton and Dunstable University Hospital, where Louise Asser and her colleagues have been using small bowel capsule endoscopy, to review patients with an increased calprotectin but normal colonoscopy, to investigate them for small bowel pathology and re-evaluate presumed false positive calprotectin results.
